Browse our comprehensive collection of market intelligence reports.
The global hepatitis diagnostics market supports early disease identification, treatment selection, therapeutic monitoring, and population-level screening across viral hepatitis infections. Demand is shifting toward molecular diagnostics and automated laboratory platforms because healthcare systems are prioritizing earlier detection to reduce long-term complications such as cirrhosis and hepatocellular carcinoma. This transition increases the importance of high-sensitivity assays capable of i
The global companion diagnostics market is becoming an integral component of precision medicine because therapeutic decision-making increasingly depends on validated biomarker identification rather than disease classification alone. Drug developers, diagnostic manufacturers, healthcare providers, and regulatory agencies are expanding coordinated development models that align diagnostic assays with targeted therapeutics throughout clinical development. This integration supports patient stratif
The lung cancer diagnostics market is becoming increasingly centered on precision medicine as clinical decision-making depends on biomarker-driven patient stratification rather than histological classification alone. Diagnostic demand is expanding beyond initial disease confirmation because clinicians are requiring comprehensive molecular characterization to guide targeted therapies, immunotherapies, and longitudinal disease monitoring. This transition places molecular diagnostics, liquid bio
The global portable PCR market supports decentralized molecular diagnostics by enabling rapid nucleic acid amplification outside conventional laboratory settings. The market is serving healthcare providers, public health agencies, veterinary laboratories, food safety authorities, environmental monitoring organizations, and research institutions that require accurate molecular testing at the point of need. Demand is shifting from centralized laboratory workflows toward field-deployable diagnos
The molecular infectious disease diagnostics market is becoming a central component of infectious disease management as healthcare systems prioritize rapid pathogen identification, antimicrobial stewardship, and decentralized diagnostic capabilities. Molecular diagnostics detect pathogen-specific nucleic acids with high analytical sensitivity, allowing clinicians to identify infections before conventional culture-based methods provide actionable results. This capability is changing clinical d
The infectious disease diagnostics market is becoming a critical component of global healthcare because timely pathogen identification directly influences treatment selection, antimicrobial stewardship, outbreak surveillance, and healthcare resource utilization. Healthcare providers increasingly require diagnostic platforms capable of delivering clinically actionable results within shorter turnaround times while maintaining analytical sensitivity across diverse infectious agents. This demand
Clinical sequencing is becoming an integral component of precision medicine because it enables comprehensive genomic characterization that directly informs diagnosis, prognosis, therapeutic selection, and disease monitoring. Demand is shifting from research-centric sequencing toward clinically validated workflows as healthcare providers are integrating genomic evidence into routine medical decision-making. This transition increases the requirement for standardized sequencing platforms, robust
The breast cancer diagnostics market is undergoing a structural transition as healthcare systems are placing greater emphasis on early disease detection, precision oncology, and biomarker-driven clinical decision-making. Diagnostic technologies are extending beyond conventional mammography and histopathology toward molecular diagnostics, artificial intelligence (AI)-assisted imaging, liquid biopsy, and multi-omics profiling, reflecting the increasing complexity of breast cancer management. Th
The global genomic biomarkers market supports disease characterization by identifying DNA- and RNA-based molecular signatures that guide diagnosis, prognosis, therapeutic selection, and treatment monitoring. Demand is shifting from single-gene testing toward comprehensive genomic profiling because clinicians require higher analytical precision for personalized treatment decisions across oncology, inherited disorders, infectious diseases, and chronic conditions. This transition is increasing d
The next-generation sequencing (NGS) market is becoming a foundational component of precision medicine, translational research, infectious disease surveillance, reproductive health, and oncology diagnostics. Sequencing platforms enable parallel analysis of millions of DNA or RNA fragments, allowing healthcare providers and researchers to generate comprehensive genomic information with greater speed and analytical depth than conventional sequencing technologies. Clinical laboratories are incre
Hydraulic valves remain fundamental components within fluid power systems, controlling pressure, flow, and fluid direction across construction equipment, agricultural machinery, industrial manufacturing systems, mining equipment, transportation assets, and oil and gas installations. Market demand is shaped less by standalone valve purchases than by capital investment in hydraulic equipment, replacement cycles, maintenance activity, and machine modernization. Buyers increasingly evaluate hydra
Non-alcoholic beers are exactly what their name implies: beers without alcohol. The non-alcoholic form, however, contains a small amount of alcohol; this is often made by dehydrating carbohydrates with yeast and other enzymes. Beer with no alcohol has a maximum alcohol concentration of 0.05 percent ABV; a beer that has been de-alcoholized has a maximum alcohol content of 0.5 percent; and a beer that has been brewed with less alcohol has a maximum alcohol content of 1.2 percent.